BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2133 related articles for article (PubMed ID: 18068536)

  • 1. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
    Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
    Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?
    Deluche L; Joha S; Corm S; Daudignon A; Geffroy S; Quief S; Villenet C; Kerckaert JP; Laï JL; Preudhomme C; Roche-Lestienne C
    Genes Chromosomes Cancer; 2008 Dec; 47(12):1110-7. PubMed ID: 18767145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
    Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
    Metzke-Heidemann S; Harder L; Gesk S; Schoch R; Jenisch S; Grote W; Siebert R; Schlegelberger B
    Genes Chromosomes Cancer; 2001 May; 31(1):10-4. PubMed ID: 11284030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia.
    Pullarkat ST; Vardiman JW; Slovak ML; Rao DS; Rao NP; Bedell V; Said JW
    Leuk Res; 2008 Nov; 32(11):1770-5. PubMed ID: 18417213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. t(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia.
    Yin CC; Medeiros LJ; Glassman AB; Lin P
    Am J Clin Pathol; 2004 Jun; 121(6):836-42. PubMed ID: 15198355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL.
    Onozawa M; Fukuhara T; Takahata M; Yamamoto Y; Miyake T; Maekawa I
    Ann Hematol; 2003 Sep; 82(9):593-5. PubMed ID: 12898186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-resolution analysis of acquired genomic imbalances in bone marrow samples from chronic myeloid leukemia patients by use of multiple short DNA probes.
    Reid AG; Tarpey PS; Nacheva EP
    Genes Chromosomes Cancer; 2003 Jul; 37(3):282-90. PubMed ID: 12759926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
    Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myeloid leukemia in blast phase associated with t(3;8)(q26;q24).
    Lin P; Lennon PA; Yin CC; Abruzzo LV
    Cancer Genet Cytogenet; 2009 Sep; 193(2):119-22. PubMed ID: 19665075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Megakaryocytic blast crisis in a chronic myeloid leukemia patient with a rare variant of Philadelphia rearrangement t(9;22;22) and a constitutional translocation t(3;7).
    Jarmuz M; Kroll R; Przybyłowicz-Chalecka A; Ratajczak B; Gniot M; Szyfter K; Komarnicki M
    Cancer Genet Cytogenet; 2010 May; 199(1):45-7. PubMed ID: 20417868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blast crisis accompanied by severe DIC of Ph negative chronic myeloid leukemia showing t(9;16) and positive M-BCR/ABL rearrangement].
    Fujiwara H; Takahashi N; Tada J; Higuchi T; Harada H; Mori H; Niikura H; Omine M; Fujita K
    Rinsho Ketsueki; 1997 Aug; 38(8):663-68. PubMed ID: 9311272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular biology of chronic myeloid leukemia].
    Hellmann A
    Acta Haematol Pol; 1992; 23(2 Suppl 1):13-7. PubMed ID: 1488867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
    Agirre X; Román-Gómez J; Vázquez I; Jiménez-Velasco A; Larráyoz MJ; Lahortiga I; Andreu EJ; Márquez J; Beltrán de Heredia JM; Odero MD; Prósper F; Calasanz MJ
    Cancer Genet Cytogenet; 2005 Jul; 160(1):22-6. PubMed ID: 15949566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 107.